6CM
NYMX

683 Capital Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

683 Capital Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-85,763
Closed -$189K – 187
2019
Q4 		$189K Buy
+85,763
New +$169K 0.02% 116

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

683 Capital Management's NYMX Position: Q1 2020 in Review

683 Capital Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2020, closing a stake of 85,763 shares — an estimated $189K sold.

683 Capital Management first reported a position in NYMX in Q4 2019 and held it in 1 quarter. The position peaked at $189K in Q4 2019. 47 funds tracked by Wall St. Rank hold NYMX as of Q1 2020.

  • 683 Capital Management reported no remaining Nymox Pharmaceutical Corp position as of Q1 2020 after selling out during the quarter.
  • 683 Capital Management sold 85,763 Nymox Pharmaceutical Corp shares in Q1 2020, an estimated $189K.
  • 683 Capital Management first reported a position in Nymox Pharmaceutical Corp in Q4 2019 and held it in 1 quarter.
  • 683 Capital Management's Nymox Pharmaceutical Corp position peaked at $189K in Q4 2019.
  • 47 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.